在丙型肝炎病毒1b型感染中，来迪派韦/索磷布韦治疗失败后非结构蛋白5A/P32缺失 - Suppr

Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection.

作者信息

Doi Akira, Hikita Hayato, Sakamori Ryotaro, Tahata Yuki, Kai Yugo, Yamada Ryoko, Yakushijin Takayuki, Mita Eiji, Ohkawa Kazuyoshi, Imai Yasuharu, Furuta Kunimaro, Kodama Takahiro, Tatsumi Tomohide, Takehara Tetsuo

机构信息

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.

Department of Gastroenterology and Hepatology, Osaka General Medical Center, Osaka, Japan.

出版信息

Hepatology. 2018 Jul;68(1):380-383. doi: 10.1002/hep.29836. Epub 2018 May 14.

DOI:10.1002/hep.29836

PMID:29425404

Abstract

摘要

相似文献

Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection.在丙型肝炎病毒1b型感染中，来迪派韦/索磷布韦治疗失败后非结构蛋白5A/P32缺失

Hepatology. 2018 Jul;68(1):380-383. doi: 10.1002/hep.29836. Epub 2018 May 14.

NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.在一名合并感染HIV-1的患者中，NS5A耐药导致索磷布韦/维帕他韦与利巴韦林联合进行24周治疗未能治愈丙型肝炎基因1a型感染。

J Clin Virol. 2016 Sep;82:66-69. doi: 10.1016/j.jcv.2016.06.012. Epub 2016 Jun 23.

Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.索磷布韦和来迪派韦无利巴韦林治疗 12 周对肝移植后复发的丙型肝炎病毒 1b 型感染高度有效：日本多中心经验。

J Gastroenterol. 2017 Aug;52(8):986-991. doi: 10.1007/s00535-017-1310-9. Epub 2017 Jan 30.

NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.NS5A 耐药相关变异削弱了 ledipasvir 和 sofosbuvir 对感染 HCV 基因 1b 型肝硬化患者的疗效。

J Gastroenterol. 2017 Jul;52(7):845-854. doi: 10.1007/s00535-016-1290-1. Epub 2016 Dec 2.

The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.在一个真实世界队列中，多种NS5A耐药相关替代位点（RASs）的存在与初治慢性丙型肝炎1b型感染患者接受索磷布韦和来迪帕司韦治疗的结果相关。

J Viral Hepat. 2018 May;25(5):535-542. doi: 10.1111/jvh.12850. Epub 2018 Jan 17.

High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.在真实世界中，对失败于 NS5A 抑制剂的 HCV 患者进行耐药指导的再治疗具有很高的疗效。

J Hepatol. 2019 Nov;71(5):876-888. doi: 10.1016/j.jhep.2019.06.022. Epub 2019 Jul 4.

Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis.来迪派韦与索磷布韦联合治疗丙型肝炎病毒1型感染：系统评价与荟萃分析

Ann Hepatol. 2017 March-April;16(2):188-197. doi: 10.5604/16652681.1231562.

Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.接受不含索磷布韦的含来迪帕司韦方案治疗的慢性丙型肝炎患者的非结构蛋白5A耐药谱

J Viral Hepat. 2018 Feb;25(2):126-133. doi: 10.1111/jvh.12783. Epub 2017 Oct 4.

Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.索磷布韦、聚乙二醇干扰素和利巴韦林用于索磷布韦和来迪帕司韦治疗失败后的丙型肝炎病毒1b型再治疗。

Hepatology. 2018 May;67(5):2049-2050. doi: 10.1002/hep.29667. Epub 2018 Mar 25.

Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?索磷布韦与达拉他韦联合利巴韦林或不联合利巴韦林治疗 1 型和 2 型丙型肝炎病毒：在低收入国家，泛基因型治疗的一种可能替代方案？

Int J Infect Dis. 2021 Jun;107:166-169. doi: 10.1016/j.ijid.2021.04.061. Epub 2021 Apr 22.

引用本文的文献

Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir.格卡瑞韦/哌仑他韦治疗后 12 周获得持续病毒学应答的 1b 型丙型肝炎病毒复发患者使用来迪派韦/索磷布韦有效。

Intern Med. 2023 Sep 1;62(17):2507-2511. doi: 10.2169/internalmedicine.0865-22. Epub 2022 Nov 30.

Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan.格卡瑞韦/哌柏西利对日本东京北部现实世界中丙型肝炎病毒感染患者的疗效。

J Clin Med. 2021 Nov 26;10(23):5529. doi: 10.3390/jcm10235529.

Treatment progress and expansion in Japan: From interferon to direct-acting antiviral.日本的治疗进展与拓展：从干扰素到直接作用抗病毒药物

Glob Health Med. 2021 Oct 31;3(5):321-334. doi: 10.35772/ghm.2021.01083.

Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients.治疗后患者体内检测到的新型丙型肝炎病毒 NS5A 耐药相关取代对的影响。

Sci Rep. 2019 Apr 5;9(1):5722. doi: 10.1038/s41598-019-42114-z.

Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.两种药物联合治疗方案，包括 NS3/4A 抑制剂、NS5B 抑制剂和非选择性抗病毒药物，对人源化肝脏小鼠的 NS5A-P32 缺失型丙型肝炎病毒有效。

J Gastroenterol. 2019 May;54(5):449-458. doi: 10.1007/s00535-018-01541-x. Epub 2019 Jan 25.

NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.NS5A-P32 缺失是导致接受 glecaprevir 和 pibrentasvir 治疗的患者病毒学失败的一个因素。

J Gastroenterol. 2019 May;54(5):459-470. doi: 10.1007/s00535-018-01543-9. Epub 2019 Jan 5.

Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus.克服的挑战：直接作用抗病毒治疗丙型肝炎病毒时的非结构蛋白 5A-P32 缺失。

World J Gastroenterol. 2018 Oct 14;24(38):4304-4310. doi: 10.3748/wjg.v24.i38.4304.

Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.索磷布韦维帕他韦联合利巴韦林治疗日本基因 1 型或 2 型丙型肝炎经直接作用抗病毒药物治疗失败的患者。

Hepatol Int. 2018 Jul;12(4):356-367. doi: 10.1007/s12072-018-9878-6. Epub 2018 Jul 20.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献